Tyme Technologies, Inc., was first established on November 22, 2011, formerly known as "Global Group Enterprises Corp", and was later reorganized on September 18, 2014. The company is a clinical-stage biotechnology company focused on the development of effective and low-toxic anticancer drugs, unlike targeted therapies that try to modulate specific mutations in cancer, their treatments are designed to exploit the innate metabolic weaknesses of cancer cells to destroy their defenses. The company's current main product is SM-88, which is in the preparation stage for clinical trials. 

TYME(Delisted)

TYME Profile